J&J ax­es its big BACE pro­gram in asymp­to­matic Alzheimer's pa­tients as the drum­beat of PhI­II fail­ures rolls on

Re­searchers at J&J $JNJ have pulled the plug on yet an­oth­er BACE pro­gram for Alzheimer’s.

Un­like Mer­ck, which scrapped their lead­ing BACE pro­gram for verube­ce­s­tat af­ter it clear­ly failed to help pa­tients on cog­ni­tion and func­tion in a ma­jor Phase III study, J&J was forced to halt the Phase IIb/III tri­al of atabece­s­tat (JNJ-54861911) af­ter some of the pa­tients in the drug arm be­gan to demon­strate se­ri­ous spikes in liv­er en­zymes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.